Biodesix Q2 revenue rises 34%, beats analyst estimates

Biodesix maintained FY 2026 revenue guidance at $108 million to $114 million, with the midpoint reflecting 25% growth.

The company expects to maintain gross margin of about 80% for FY 2026.

Biodesix said it expects continued improvement in adjusted EBITDA on the path to profitability.

Biodesix Q2 revenue rose 34% year over year, beating analyst expectations.

The company posted an 82% gross margin, up 200 basis points from a year earlier.

Net loss for Q2 narrowed 37% year over year to $7.3 million.

• Diagnostic testing growth — The company said 42% growth in diagnostic testing revenue was driven by a 38% increase in test volumes and higher average revenue per test.
• Reimbursement and sales force — Biodesix attributed performance to expanded reimbursement coverage and improved sales force productivity.
• Gross margin improvement — The company said higher diagnostic testing volumes, improved average revenue per test, and lab workflow optimization led to higher gross margin.